These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32865574)

  • 21. FDA's proposed rule for pregnancy and lactation labeling: improving maternal child health through well-informed medicine use.
    Feibus KB
    J Med Toxicol; 2008 Dec; 4(4):284-8. PubMed ID: 19031382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent changes in pregnancy and lactation labeling: retirement of risk categories.
    Ramoz LL; Patel-Shori NM
    Pharmacotherapy; 2014; 34(4):389-95. PubMed ID: 24390829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychiatric Medications and Reproductive Safety: Scientific and Clinical Perspectives Pertaining to the US FDA Pregnancy and Lactation Labeling Rule.
    Freeman MP; Farchione T; Yao L; Sahin L; Taylor L; Huybrechts KF; Nonacs R; Sosinsky AZ; Viguera AC; Cohen LS
    J Clin Psychiatry; 2018 Jul; 79(4):. PubMed ID: 30153401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing congenital malformation risk from medications used in pregnancy: The contribution of NBDPS in pregnancy labeling of prescription drug products.
    Tassinari MS; Sahin L; Yao LP
    Birth Defects Res A Clin Mol Teratol; 2015 Aug; 103(8):718-20. PubMed ID: 26223007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014).
    Gnanasakthy A; DeMuro C; Clark M; Haydysch E; Ma E; Bonthapally V
    J Clin Oncol; 2016 Jun; 34(16):1928-34. PubMed ID: 27069082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2016 and 2017.
    Barrow P
    Reprod Toxicol; 2018 Sep; 80():117-125. PubMed ID: 29660390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Labeling and effectiveness testing; sunscreen drug products for over-the-counter human use; delay of compliance dates. Final rule; delay of compliance dates; request for comments.
    Food and Drug Administration, HHS
    Fed Regist; 2012 May; 77(92):27591-3. PubMed ID: 22606729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA Implements New Labeling for Medications Used During Pregnancy and Lactation.
    Whyte J
    Am Fam Physician; 2016 Jul; 94(1):12-5. PubMed ID: 27386718
    [No Abstract]   [Full Text] [Related]  

  • 30. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes to Pregnancy and Lactation Risk Labeling for Prescription Drugs.
    Fantasia HC; Harris AL
    Nurs Womens Health; 2015; 19(3):266-70. PubMed ID: 26058910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety information in drug labeling: a comparison of the USA, the UK, and Japan.
    Shimazawa R; Ikeda M
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):306-18. PubMed ID: 23355452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A review of pharmaceutical labeling for overdose treatment and toxicity data.
    Mazer-Amirshahi M; Sokol G; van den Anker J; Cantilena L
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):319-23. PubMed ID: 23283832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the new pregnancy and lactation drug labeling.
    Watkins EJ; Archambault M
    JAAPA; 2016 Feb; 29(2):50-2. PubMed ID: 26818647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA labeling system for drugs in pregnancy.
    Boothby LA; Doering PL
    Ann Pharmacother; 2001 Nov; 35(11):1485-9. PubMed ID: 11724104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
    Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
    JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Over-the-counter human drugs; labeling requirements. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(51):13254-303. PubMed ID: 10557606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007.
    Momper JD; Mulugeta Y; Green DJ; Karesh A; Krudys KM; Sachs HC; Yao LP; Burckart GJ
    JAMA Pediatr; 2013 Oct; 167(10):926-32. PubMed ID: 23921678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.